Search Result

Results for "

Fibrin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) AP-1 (1) Apoptosis (1) Autophagy (2) Bacterial (5) Biochemical Assay Reagents (1) Cathepsin (1) Collagen (2) COX (2) Cytochrome P450 (1) Dengue Virus (1) Drug Isomer (1) Endogenous Metabolite (1) Environmental Pollutants (1) ERK (1) Factor Xa (6) Factor XI (2) Flavivirus (1) Fluorescent Dye (2) Heme Oxygenase (HO) (1) IKZF Family (1) Integrin (5) Interleukin Related (3) JNK (2) Kallikrein (2) Leukotriene Receptor (1) Ligands for E3 Ligase (1) Liposome (4) Molecular Glues (1) NF-κB (4) p38 MAPK (1) PAI-1 (3) Parasite (1) PERK (1) PKC (2) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Ser/Thr Protease (5) TGF-beta/Smad (2) Thrombin (21) TREM receptor (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (44) Infection (3) Inflammation/Immunology (11) Metabolic Disease (4) Neurological Disease (3)
Oligonucleotides:	Pegylated Lipids (4) Aptamers (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125864

Fibrinogen (Bovine) 2 Publications Verification	Interleukin Related NF-κB	Inflammation/Immunology
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-P3160

Fibronectin 5+ Cited Publications	Integrin	Cardiovascular Disease Inflammation/Immunology
Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans . This product is a human Fibronectin obtained by recombinant expression in a rice expression system.

HY-16268

Kartogenin Maximum Cited Publications 31 Publications Verification KGN	TGF-beta/Smad	Inflammation/Immunology
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC₅₀: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .

HY-107911

Protamine sulfate 3 Publications Verification	Thrombin	Metabolic Disease
Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer .

HY-P2373

Kinase, Natto fermentation 4 Publications Verification	PAI-1	Cardiovascular Disease
Kinase, Natto fermentation is a potent fibrinolytic enzyme. Kinase, Natto fermentation can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Kinase, Natto fermentation can be used for the research of cardiovascular diseases .

HY-W040030

Hematin 1 Publications Verification	Cytochrome P450	Metabolic Disease Cancer
Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins . Hematin can be used for the research of acute porphyrias and cancer .

HY-W145519

Hydroxyethyl starch (MW170-230 kDa)	Environmental Pollutants Biochemical Assay Reagents	Cardiovascular Disease
Hydroxyethyl starch (MW170-230 kDa) is a type of hydroxyethyl starch with a molecular weight of 170-230 kDa. A medium-molecular-weight hydroxyethyl starch (HES 200/0.62) exhibits minimal intravascular hydrolysis. The rapidly degradable medium-molecular-weight Hydroxyethyl starch 200/0.5 causes almost no coagulation disorders and improves hemorheological parameters .

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a *fibrin* polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-P10709

CREKA peptide	Collagen	Cardiovascular Disease Cancer
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .

HY-B1064

Clindamycin phosphate 4 Publications Verification Clindamycin 2-phosphate; U-28508	Bacterial Antibiotic Parasite	Infection Cancer
Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis . Clindamycin phosphate has no cytotoxicity. Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties .

HY-P0074A

GPRP acetate 3 Publications Verification Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate	Integrin	Cardiovascular Disease
GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .

HY-B0665

*Fibrin*	Integrin	Cardiovascular Disease
Fibrin is an insoluble protein found in blood that is produced in response to bleeding. As the main component of blood clots, fibrin functions in blood coagulation. Fibrin binds to the integrins ICAM-1, VE-cadherin, αIIbβ3, αMβ2, αvβ3 and α5β1. Fibrin is used in research related to chronic wounds .

HY-129056

Melagatran	Thrombin NF-κB AP-1	Cardiovascular Disease Neurological Disease
Melagatran is a reversible, selective, orally active direct inhibitor of thrombin with a K_i of 2 nM. Melagatran binds directly to the active site of thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin. Melagatran reduces the DNA binding activity of NF-κB and AP-1. Melagatran reduces fibrin deposition in organs, alleviates ischemic brain damage, and reduces the size of advanced atherosclerotic lesions. Melagatran can be used in the study of cardiovascular disease (coronary thrombosis, atherosclerosis) and ischemic brain damage .

HY-122542A

PPACK dihydrochloride 2 Publications Verification Pebac; D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone; D-Phe-Pro-Arg-CH2Cl	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK dihydrochloride is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK dihydrochloride binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK dihydrochloride also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK dihydrochloride can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-N1400

(20R)-Ginsenoside Rh1	PKC	Cardiovascular Disease
(20R)-Ginsenoside Rh1 is the R-isomer of Ginsenoside Rh1 (HY-N0604), and it is found in red ginseng, ginseng, and other sources. (20R)-Ginsenoside Rh1 inhibits thrombin-induced conversion of fibrinogen to fibrin, exerting anticoagulant and antithrombotic effects .

HY-E70127

Serratiopeptidase Brasan; Dasen	Ser/Thr Protease COX Bacterial Prostaglandin Receptor Interleukin Related	Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology Cancer
Serratiopeptidase (Brasan; Dasen) is an orally active zinc-containing metalloprotease belonging to the serralysin family. Serratiopeptidase reduces the release of inflammatory mediators such as prostaglandins, thromboxanes and interleukins by inhibiting COX, thereby relieving pain, swelling and redness. Serratiopeptidase exhibits antibiofilm, mucolytic and wound-healing activities. As a serine protease, Serratiopeptidase has the ability to dissolve blood clots, fibrin and atherosclerotic plaques. Serratiopeptidase degrades amyloid fibrils and has potential anti-Alzheimer's effects. Serratiopeptidase shows cytotoxicity against colon cancer cells .

HY-106275

FX-06 Fibrin-derived peptide Bβ15-42	Flavivirus Dengue Virus	Cardiovascular Disease
FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS) .

HY-122311

Orniplabin SMTP-7	Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS .

HY-P5232

Tetrapeptide-21	Collagen	Metabolic Disease
Tetrapeptide-21 is a bioactive peptide composed of four amino acids. Tetrapeptide-21 effectively enhances the vitality of human dermal fibroblasts. Tetrapeptide-21 upregulates the expression of key extracellular matrix (ECM) genes and promotes the synthesis of ECM proteins (such as type I collagen, hyaluronic acid synthase 1, and fibronectin). Tetrapeptide-21 has the efficacy of anti-wrinkle and improving skin elasticity, and has been reported to be used as a cosmetic ingredient .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Thrombin COX ERK JNK Factor Xa	Cardiovascular Disease Inflammation/Immunology
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-107966A

Heparin calcium (MW 3600-5000) Nadroparin calcium (MW 3600-5000)	Thrombin Factor Xa Autophagy Bacterial	Cardiovascular Disease Cancer
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-16268A

Kartogenin sodium Maximum Cited Publications 31 Publications Verification KGN sodium	TGF-beta/Smad	Inflammation/Immunology
Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC₅₀: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .

HY-P3318

Boc-Phe-Leu-Phe-Leu-Phe L-BOC2	Leukotriene Receptor	Inflammation/Immunology
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .

HY-D1480

Crystal Ponceau 6R	Fluorescent Dye	Others
Crystal Ponceau 6R is a red azo dye. Crystal Ponceau 6R used in histology, for staining fibrin with the martius, scarlet and blue (MSB) Trichrome stain .

HY-125864D

Rabbit Fibrinogen	Interleukin Related NF-κB	Cardiovascular Disease
Rabbit Fibrinogen is a native fibrinogen from rabbit plasma. Fibrinogen is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-W854721

Mn(III) Protoporphyrin IX chloride Manganese(III) Protoporphyrin IX Chloride	Heme Oxygenase (HO)	Metabolic Disease
Mn(III) protoporphyrin IX chloride is a metalloporphyrin. It induces mRNA expression of the genes encoding δ-aminolevulinate synthase and heme oxygenase (HO), enzymes that catalyze the rate-limiting steps of heme biosynthesis and degradation, respectively, in chick embryo liver cells when used at a concentration of 10 μM. Mn(III) protoporphyrin IX chloride-containing nanobialys have been used in magnetic resonance imaging (MRI) of fibrin clots in vitro. It has also been used in the synthesis of Mn(III) protoporphyrin IX-6(7)-glycyl-glycyl-L-histidine methyl ester (MnGGH), a metalloporphyrin conjugate with microperoxidase activity.

HY-114150

D-Val-Leu-Arg-pNA	PAI-1	Others
D-Val-Leu-Arg-pNA is a glandular kininoreleasing enzyme substrate that also acts as a substrate for tissue-type plasminogen activator (t-PA) with no apparent affinity for fibrin .

HY-76971

Dechloro Rivaroxaban	Factor Xa	Cardiovascular Disease
Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a K_i of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC₅₀s of 2.1 nM and 92 nM, respectively .

HY-P991029

Sutacimig HMB-001	Thrombin Ser/Thr Protease TREM receptor	Cardiovascular Disease
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia .

HY-114164H

Human α-Thrombin (Lyophilized) 5+ Cited Publications	Thrombin	Cardiovascular Disease
Human α-thrombin is a multifunctional serine protease that plays a pivotal role in the coagulation pathway. Human α-thrombin cleaves fibrinogen and converts it into fibrin. Human α-thrombin can stimulate platelet activation and stabilize fibrin polymers .

HY-15759A

Napsagatran hydrate Ro 46-6240 hydrate; Ro 46-6240/010 hydrate	Thrombin	Cardiovascular Disease
Napsagatran (Ro 46-6240) hydrate is a potent thrombin inhibitor. Napsagatran hydrate exhibits anticoagulant effects in vitro and in vivo. Napsagatran hydrate can be used in antithrombotic research ^[1][2].

HY-107966

Heparin calcium (MW 15000-19000) Nadroparin calcium (MW 15000-19000)	Thrombin Factor Xa Autophagy Bacterial	Cardiovascular Disease Cancer
Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-172497

DSPE-PEG2000-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-P991211

Bemiltenase alfa STSP-0601	Factor XI	Cardiovascular Disease
Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .

HY-106058

NCO-700	Cathepsin Apoptosis	Cardiovascular Disease Cancer
NCO-700 is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC₅₀ values of 0.8 and 46 μM, respectively. NCO-700 reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 can be used to study myocardial ischemia and refractory hormone-independent tumors .

HY-P2708

H-Gly-Pro-Arg-Pro-NH2	Integrin	Cardiovascular Disease
H-Gly-Pro-Arg-Pro-NH2 is a peptide that mimics the N-terminal Gly-Pro-Arg region in the a chain of fibrin protein. H-Gly-Pro-Arg-Pro-NH2 prevents fibrin polymerization .

HY-P10293

NQEQVSP	Thrombin Others	Others
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization .

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) sulfated	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

HY-E70230

Staphylokinase, staphylococcus aureus SAK	Ser/Thr Protease	Cardiovascular Disease
Staphylokinase, staphylococcus aureus (SAK) is a fibrin-specific plasminogen activator. Staphylokinase is an efficient, fibrin-selective thrombolytic agent .

HY-122311A

Bis(2R,3R)-Orniplabin Bis(2R,3R)-SMTP-7	Drug Isomer	Cardiovascular Disease Inflammation/Immunology
Bis(2R,3R)-Orniplabin is an isomer of Orniplabin (HY-122311). Orniplabin (SMTP-7) is a low molecular weight compound that enhances plasminogen-fibrin binding, urokinase-catalyzed plasminogen activation, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin exhibits potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits reactive oxygen species (ROS) .

HY-177804

Thrombin aptamer sodium	Thrombin	Inflammation/Immunology
Thrombin aptamer is a 11mer-DNA aptamer that targets thrombin. Thrombin aptamer inhibites thrombin-catalysed fibrin-clot formation in vitro

HY-15759

Napsagatran Ro 46-6240; Ro 46-6240/010	Thrombin	Cardiovascular Disease
Napsagatran (Ro 46-6240) is a potent thrombin inhibitor. Napsagatran exhibits anticoagulant effects in vitro and in vivo. Napsagatran can be used in antithrombotic research ^[1][2].

HY-123120

SA-152	Thrombin	Others
SA-152 is an organophosphorus inhibitor. SA-152 modulates the fibrinogen coagulation and TAME esterase activity of bovine α-thrombin .

HY-P991213

Nonacog gamma Rixubis	Factor XI	Cardiovascular Disease
Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B .

HY-12586

AZD6564	Thrombin	Others
AZD6564 is an orally active inhibitor for fibrinolysis through disruption of plasma kinase-fibrin interaction. AZD6564 dissolves human plasma clot with an IC₅₀ of 0.44 μM. AZD6564 ameliorates hemorrhage in rats with EC₅₀ of 1.62 μM, and exhibits good pharmacokinetic characteristics in rats .

HY-172496

DSPE-PEG1000-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-P3082

SKF 106760	Endogenous Metabolite	Cardiovascular Disease
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .

HY-124499

RUC-1	Integrin	Cardiovascular Disease
RUC-1 (Compound 1) is an inhibitor for αIIbβ3 integrin. RUC-1 inhibits fibrin deposition and platelet aggregation in hybrid hαIIb/mβ3 receptors expressing mice. RUC-1 exhibits antithrombotic effect in hαIIb/mβ3 receptor expressing mice .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library

1,437 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,437 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Cat. No.	Product Name	Type

HY-125864

Fibrinogen (Bovine)

2 Publications Verification

Biochemical Assay Reagents

Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-P3160

Fibronectin 5+ Cited Publications	Biochemical Assay Reagents
Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans . This product is a human Fibronectin obtained by recombinant expression in a rice expression system.

HY-W145519

Hydroxyethyl starch (MW170-230 kDa)	Biochemical Assay Reagents
Hydroxyethyl starch (MW170-230 kDa) is a type of hydroxyethyl starch with a molecular weight of 170-230 kDa. A medium-molecular-weight hydroxyethyl starch (HES 200/0.62) exhibits minimal intravascular hydrolysis. The rapidly degradable medium-molecular-weight Hydroxyethyl starch 200/0.5 causes almost no coagulation disorders and improves hemorheological parameters .

HY-107966A

Heparin calcium (MW 3600-5000) Nadroparin calcium (MW 3600-5000)	Biochemical Assay Reagents
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-107966

Heparin calcium (MW 15000-19000) Nadroparin calcium (MW 15000-19000)	Biochemical Assay Reagents
Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-172497

DSPE-PEG2000-Mal-Cys-REKA	Biochemical Assay Reagents
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-Mal-Cys-REKA	Biochemical Assay Reagents
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA	Biochemical Assay Reagents
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA	Biochemical Assay Reagents
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a *fibrin* polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-P10709

CREKA peptide	Collagen	Cardiovascular Disease Cancer
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .

HY-P0074A

GPRP acetate 3 Publications Verification Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate	Integrin	Cardiovascular Disease
GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .

HY-106275

FX-06 Fibrin-derived peptide Bβ15-42	Flavivirus Dengue Virus	Cardiovascular Disease
FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS) .

HY-P5232

Tetrapeptide-21	Collagen	Metabolic Disease
Tetrapeptide-21 is a bioactive peptide composed of four amino acids. Tetrapeptide-21 effectively enhances the vitality of human dermal fibroblasts. Tetrapeptide-21 upregulates the expression of key extracellular matrix (ECM) genes and promotes the synthesis of ECM proteins (such as type I collagen, hyaluronic acid synthase 1, and fibronectin). Tetrapeptide-21 has the efficacy of anti-wrinkle and improving skin elasticity, and has been reported to be used as a cosmetic ingredient .

HY-P3318

Boc-Phe-Leu-Phe-Leu-Phe L-BOC2	Leukotriene Receptor	Inflammation/Immunology
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .

HY-P5121A

γ-Fibrinogen 377-395 TFA	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 TFA is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 TFA blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 TFA can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

HY-114150

D-Val-Leu-Arg-pNA	PAI-1	Others
D-Val-Leu-Arg-pNA is a glandular kininoreleasing enzyme substrate that also acts as a substrate for tissue-type plasminogen activator (t-PA) with no apparent affinity for fibrin .

HY-P2708

H-Gly-Pro-Arg-Pro-NH2	Integrin	Cardiovascular Disease
H-Gly-Pro-Arg-Pro-NH2 is a peptide that mimics the N-terminal Gly-Pro-Arg region in the a chain of fibrin protein. H-Gly-Pro-Arg-Pro-NH2 prevents fibrin polymerization .

HY-P10293

NQEQVSP	Thrombin Peptides	Others
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization .

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) sulfated	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

HY-P3531

Fibrinogen γ-chain (397-411)	Peptides	Others
Fibrinogen γ-chain (397-411), a esidues 397-411 of the γ chain of fibrinogen, is a site recognizing the platelet receptor, which is distinct from the site(s) involved in polymerization of fibrin monomers .

HY-P1493A

Fibrinopeptide B, human TFA FPB,human TFA	Peptides	Inflammation/Immunology
Fibrinopeptide B, human TFA (FPB,human TFA), human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin .

HY-P3082

SKF 106760	Endogenous Metabolite	Cardiovascular Disease
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .

HY-P5356

H-D-Val-Leu-Lys-AFC Plasmin substrate	Fluorescent Dye	Others
H-D-Val-Leu-Lys-AFC (Plasmin substrate) is a biological active peptide. (This is a fluorescent plasmin substrate, Abs/Em=380/500 nm.Plasmin belongs to the family of serine proteases. It plays a key role in fibrinolysis by dissolving fibrin in blood clots. Besides fibrinolysis, plasmin is also involved in such physiological and pathological processes as wound healing, liver repair, and the maintenance of liver homeostasis.)

HY-P5121

γ-Fibrinogen 377-395	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

HY-P11209

Knob A peptide GPRPFPAC	Thrombin	Cardiovascular Disease
Knob A peptide GPRPFPAC is a fibrin knob peptide. PEGylated Knob A peptide GPRPFPAC has enhanced anticoagulant activity .

HY-P2102

BCH-2763	Thrombin	Cardiovascular Disease
BCH-2763 is a potent and selective Thrombin inhibitor. BCH-2763 has a very high affinity for thrombin (K_i = 0.11 nM). BCH-2763 can effectively inhibit fibrin formation, platelet aggregation, and free thrombin activity. BCH-2763 can be used for the study of thrombosis .

HY-P4269

Glycylglycylcysteine	Peptides	Cardiovascular Disease
Glycylglycylcysteine is a Thrombin Activatable Fibrinolysis Inhibitor (TAFI) inhibitor with a K_i of 0.99 μM and a IC₅₀ of 9.4 μM in TAFI substrate assays. TAFI is a basic carboxypeptidase that functions as a fibrinolysis inhibitor through the cleavage of C-terminal lysine on partially degraded fibrin .

HY-P11467

Gy-CATH	Bacterial p38 MAPK NF-κB PERK JNK	Cardiovascular Disease Infection
Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991029

Sutacimig HMB-001	Thrombin Ser/Thr Protease TREM receptor	Cardiovascular Disease
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia .

HY-P991211

Bemiltenase alfa STSP-0601	Factor XI	Cardiovascular Disease
Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .

HY-P991213

Nonacog gamma Rixubis	Factor XI	Cardiovascular Disease
Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B .

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3) Rat (1) Mouse (1)
Application:	IHC-P (3) ICC/IF (1) WB (3) ELISA (1)
Isotype:	IgG (2) IgG1 (1)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81886

	Factor XIIIa Antibody (YA1631) Coagulation factor XIIIa; F13A; F13a1; Fibrin stabilizing factor; A subunit; Fibrinoligase; TGase; Transglutaminase A chain	WB, IHC-P	Human
	Factor XIIIa Antibody (YA1631) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Factor XIIIa.

HY-P81886A

	Factor XIIIa Antibody (YA1631)(PBS only) Coagulation factor XIIIa; F13A; F13a1; Fibrin stabilizing factor; A subunit; Fibrinoligase; TGase; Transglutaminase A chain	WB, IHC-P	Human
	Factor XIIIa Antibody (YA1631) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Factor XIIIa.

HY-P85912

	Factor XIIIa Antibody (YA5604) bA525O21.1; coagulation factor XIII, A1 polypeptide; Coagulation factor XIII A chain; Coagulation factor XIII A1 polypeptide; Coagulation factor XIII A1 subunit; Coagulation factor XIII, A polypeptide; Coagulation factor XIIIa; F13A; F13A_HUMAN; F13a1; Factor XIIIA; Fibrin stabilizing factor, A subunit; Fibrinoligase; FSF, A subunit; Protein glutamine gamma glutamyltransferase A chain; Protein-glutamine gamma-glutamyltransferase A chain; TGase; Transglutaminase A chain; Transglutaminase, plasma; Transglutaminase. plasma	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat
	Factor XIIIa Antibody (YA5604) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Factor XIIIa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-172497

DSPE-PEG2000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-177804

Thrombin aptamer sodium		Aptamers
Thrombin aptamer is a 11mer-DNA aptamer that targets thrombin. Thrombin aptamer inhibites thrombin-catalysed fibrin-clot formation in vitro

HY-172496

DSPE-PEG1000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Fibrin

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Antibodies

Oligonucleotides

Natural
Products